StreetInsider.com News Articles

Form 8-K ONCOLYTICS BIOTECH INC For: Oct 14

Wed, 14 Oct 2026 09:33:00 -0400

si-local-file:///var/storage/secattach/20261014/27185126.html

Oncolytics updates GOBLET study timeline, expects PanCAN grant payment

Wed, 14 Oct 2026 09:30:45 -0400

Oncolytics Biotech Inc. (Nasdaq: ONCY) provided an update on its GOBLET Phase 1/2 clinical study on Oct. 14, 2026, stating it expects to receive a final grant payment from the Pancreatic Cancer Action Network (PanCAN) before the end of the quarter, following the completion of certain activities in Cohort 5 of the study.

The company said enrollment in the GOBLET study is complete and it is winding down the broader study infrastructure while continuing patient treatment and follow-up. Final results from Cohort 4, which evaluates pelareorep with atezolizumab in patients with second-line and later squamous cell anal carcinoma, are expected in

Oncolytics Biotech® Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant Payment

Wed, 14 Oct 2026 09:30:00 -0400

Completion of enrollment earlier this year and expected final PanCAN grant payment this quarter mark successful completion of a key phase of Cohort 5

Final Cohort 4 results expected in Q4 2026; initial Cohort 5 results expected in the first half of 2027

The Company will use the clinical data to focus and guide its strategy to combine pelareorep with a checkpoint inhibitor in gastrointestinal and additional tumors

SAN DIEGO, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing

Oncolytics Biotech® Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant Payment

Wed, 14 Oct 2026 09:30:00 -0400

Completion of enrollment earlier this year and expected final PanCAN grant payment this quarter mark successful completion of a key phase of Cohort 5

Final Cohort 4 results expected in Q4 2026; initial Cohort 5 results expected in the first half of 2027

The Company will use the clinical data to focus and guide its strategy to combine pelareorep with a checkpoint inhibitor in gastrointestinal and additional tumors

SAN DIEGO, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing

Form 8-K ONCOLYTICS BIOTECH INC For: Oct 12

Tue, 13 Oct 2026 08:11:00 -0400

si-local-file:///var/storage/secattach/20261013/27177616.html

Oncolytics Biotech updates patent portfolio for pelareorep

Mon, 12 Oct 2026 16:06:16 -0400

Oncolytics Biotech Inc. (Nasdaq: ONCY) provided an update on its intellectual property strategy for pelareorep, its investigational cancer immunotherapy, according to a company statement released Oct. 12, 2026.

A new method of use patent covering pelareorep as an immunotherapy for cancer has been issued in several countries, with the corresponding U.S. patent expected to issue in the near term. The company's existing manufacturing patent protection runs through 2044, and the new method of use patents are intended to extend protection into the late 2040s, subject to patent issuance and applicable patent terms.

Oncolytics has three patent application families pending, including multiple method

Oncolytics Biotech updates patent portfolio for pelareorep

Mon, 12 Oct 2026 16:06:16 -0400

Oncolytics has three patent application families pending, including multiple method

Oncolytics Biotech® Secures Patent Protection to Late 2040s and Provides Intellectual Property Portfolio Update

Mon, 12 Oct 2026 16:05:00 -0400

New method of use patent covering pelareorep as an immunotherapy for cancer has been issued in several countries, with U.S. issuance expected in the near term

Three patent applications are pending, including two method of use with one expected to be converted to a Track One application this quarter

Company expects to add a new composition of matter patent covering “next generation” pelareorep

SAN DIEGO, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today provided an update on

Oncolytics Biotech® Secures Patent Protection to Late 2040s and Provides Intellectual Property Portfolio Update

Mon, 12 Oct 2026 16:05:00 -0400

New method of use patent covering pelareorep as an immunotherapy for cancer has been issued in several countries, with U.S. issuance expected in the near term

Three patent applications are pending, including two method of use with one expected to be converted to a Track One application this quarter

Company expects to add a new composition of matter patent covering “next generation” pelareorep

Form DEFA14A ONCOLYTICS BIOTECH INC

Tue, 06 Oct 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20261006/27155896.html

Form DEF 14A ONCOLYTICS BIOTECH INC For: Dec 31

Tue, 06 Oct 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20261006/27155883.html

Form 8-K ONCOLYTICS BIOTECH INC For: Sep 29

Tue, 29 Sep 2026 09:35:00 -0400

si-local-file:///var/storage/secattach/20260929/27119066.html

Oncolytics publishes pelareorep liver cancer immune response data

Tue, 29 Sep 2026 09:30:50 -0400

Oncolytics Biotech Inc. (NASDAQ: ONCY) announced that data published in the Proceedings of the National Academy of Sciences show its investigational drug pelareorep can shift an immunologically inactive liver cancer tumor microenvironment to an active state, potentially making tumors susceptible to immune-based therapies.

The paper, titled "MicroRNA-driven regulation of immunosuppressive microenvironment in hepatocellular carcinoma," was published on Sept. 28, 2026. The preclinical data show that pelareorep infection reversed several markers of immune suppression in hepatocellular carcinoma, including increases in PD-L1 expression, Inducible T cell Costimulatory Ligand levels on tumor cells, and CD8+ T cell density.

Hepatocellular carcinoma typically presents with low CD8+

Oncolytics publishes pelareorep liver cancer immune response data

Tue, 29 Sep 2026 09:30:50 -0400

Hepatocellular carcinoma typically presents with low CD8+

Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy

Tue, 29 Sep 2026 09:30:00 -0400

SAN DIEGO, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced data published in the Proceedings of the National Academy of Sciences show pelareorep’s ability to change an immunologically inactive liver cancer tumor microenvironment into one that is immunologically active and potentially susceptible to immune-based therapy. The academic paper titled “MicroRNA-driven regulation of immunosuppressive microenvironment in hepatocellular carcinoma” was published in Proceedings of the National Academy of Sciences on September 28, 2026 (link to the paper). Pelareorep is an

Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy

Tue, 29 Sep 2026 09:30:00 -0400

Form 8-K ONCOLYTICS BIOTECH INC For: Sep 28

Mon, 28 Sep 2026 09:32:00 -0400

si-local-file:///var/storage/secattach/20260928/27111118.html

Oncolytics Biotech® Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer Study

Mon, 28 Sep 2026 09:30:00 -0400

Substantially all planned REO 033 clinical sites are now activated, with multiple patients currently on study

Company expects to have sufficient Part A data to provide an interim clinical update by year-end 2026

FDA alignment provides potential path to accelerated approval based on objective response rate and full approval based on progression-free survival

SAN DIEGO, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced continued clinical and operational progress in REO

Oncolytics Biotech® Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer Study

Mon, 28 Sep 2026 09:30:00 -0400

Substantially all planned REO 033 clinical sites are now activated, with multiple patients currently on study

Company expects to have sufficient Part A data to provide an interim clinical update by year-end 2026

FDA alignment provides potential path to accelerated approval based on objective response rate and full approval based on progression-free survival

Three Nasdaq Cancer Developers Under $10 Advance Clinical Programs

Fri, 11 Sep 2026 08:45:00 -0400

NeOnc reports Phase 2a brain cancer data as BriaCell and Oncolytics advance breast and colorectal cancer studies

DENVER, Sept. 11, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – Recent cancer treatment advances span new FDA approvals and ongoing Phase 2 and Phase 3 clinical programs. NeOnc Technologies Holdings (NASDAQ: NTHI), BriaCell Therapeutics (NASDAQ: BCTX) and Oncolytics Biotech (NASDAQ: ONCY) have reported clinical and regulatory developments across brain, breast and colorectal cancer, and all three have recently traded below $10.

NeOnc: Positive Phase 2a brain cancer results